Diagnosis and treatment of hepatitis C

Journal of the Royal Society of Medicine

Volumn 97, Issue 5, 2004, Pages 223-225

  D'Souza, Raymond ^a   Foster, Graham R ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ERYTHROPOIETIN; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS ANTIBODY; ALPHA2B INTERFERON; HEPATITIS C ANTIBODY;

ANXIETY; AUTOIMMUNE HEPATITIS; CLINICAL TRIAL; COUGHING; CRYOGLOBULINEMIA; DEPRESSION; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEVER; FLU LIKE SYNDROME; GENOTYPE; HAIR LOSS; HEMOLYTIC ANEMIA; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS NON A NON B; HUMAN; INCUBATION TIME; LICHEN PLANUS; LIVER BIOPSY; LIVER CELL CARCINOMA; MEMBRANOUS GLOMERULONEPHRITIS; NAUSEA; NEUTROPENIA; NONHUMAN; PARANOIA; POLYARTERITIS NODOSA; POLYMERASE CHAIN REACTION; PREVALENCE; RASH; REMISSION; REVIEW; SEROLOGY; SEXUAL TRANSMISSION; SIDE EFFECT; SJOEGREN SYNDROME; THROMBOCYTOPENIA; THYROID DISEASE; THYROIDITIS; VERTICAL TRANSMISSION; VIROLOGY; VIRUS IDENTIFICATION; VIRUS TRANSMISSION; BLOOD; PATIENT SELECTION;

ANTIVIRAL AGENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; PATIENT SELECTION;

EID: 2442670754     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1258/jrsm.97.5.223     Document Type: Review

References (23)

1. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood borne non-A, non-B viral hepatitis clone. Science 1989;244:359-61
2. Global surveillance and control of hepatitis C. Report of a WHO Consultation organised in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Virol Hep 1999;6: 635-47
3. Armstrong GL, Alter MJ, McQuillan GM, et al. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000;31: 777-89
4. Zuckerman A. The elusive hepatitis C virus. BMJ 1989;299:871-3
5. Di Bisceglie A, Goodman Z, Ishak K, et al. Long-term clinical and histological follow up of chronic posttransfusion hepatitis. Hepatology 1991;14:969-74
6. El-Ahmady O, Halim A, Mansour O, et al. Incidence of hepatitis C virus in Egyptians. J Hepatol 1994;21:687
7. Bresters D, Mauser-Bunschoten EP, Reesink HW, et al. Sexual transmission of hepatitis C virus. Lancet 1993;342:210-11
8. Giovannini M, Tagger A, Ribero ML, et al. Maternal-infant transmission of hepatitis C virus and HIV infections: a possible interaction. Lancet 1990;335:1166
9. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349: 825-32
10. Lunel F. Hepatitis C virus and autoimmunity: fortuitous association or reality? Gastroenterology 1994;107:1550-5
11. Marcellin P, Descamps V, Martinot-Peignoux M, et al. Cryoglobulinaemia with vasculitis associated with hepatitis C virus infection. Gastroenterology 1993;104:272-7
12. Bruix J, Calvet X, Costa J, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989;334:1004-6
13. Courouce A-M, Bouchardeau F, Girault A, et al. Significance of NS3 and NS5 antigens in screening for HCV antibody. Lancet 1994;343:853-4
14. Davis G. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002;36:S145-51
15. National Institutes of Health Consensus Development Conference. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002. June 10-12, 2002. Hepatology 2002;36:S128-34
16. National Institutes of Health Consensus Development Conference Panel Statement: Management of hepatitis C. Hepatology 1997;26(suppl. 1):2S-10S
17. McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 1999;19:57-6S
18. National Institutes of Health Consensus Development Conference National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002. June 10-12, 2002. Hepatology 2002;36:S3-20
19. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon a2b plus ribavirin compared with interferon a2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-65
20. Fried MW, Shiffman ML, Reddy R, Smith C, et al. Peginterferon a2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82
21. Hadziyannis SJ, Sette H Jnr, Morgan TR, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004;140:346-55
22. Alberti A, Benvegnu L. Management of hepatitis C. J Hepatol 2003;38:S104-18
23. Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 2002;36:S79-84